Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases

Andrew S. Kennedy, David S. Ball, Steven J. Cohen, Michael Cohn, Douglas M. Coldwell, Alain Drooz, Eduardo Ehrenwald, Samir Kanani, Charles W. Nutting, Fred M. Moeslein, Samuel G. Putnam, Steven C. Rose, Michael A. Savin, Sabine Schirm, Navesh K. Sharma, Eric A. Wang

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: To assess response and the impact of imaging artifacts following radioembolization with yttrium-90-labeled resin microspheres (90Y-RE) based on the findings from a central independent review of patients with liver-dominant metastatic colorectal cancer (mCRC). Methods: Patients with mCRC who received 90Y-RE (SIR-Spheres® Sirtex Medical, Sydney, Australia) at nine US institutions between July 2002 and December 2011 were included in the analysis. Tumor response was assessed at baseline and 3 months using either the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 or 1.1. For each lesion, known artifacts affecting the interpretation of response (peri-tumoral edema and necrosis) were documented. Survivals (Kaplan-Meier analyses) were compared in responders [partial response (PR)] and non-responders [stable (SD) or progressive disease (PD)]. Results: Overall, 195 patients (mean age 62 years) received 90Y-RE after a median of 2 (range, 1-6) lines of prior chemotherapy. Using RECIST 1.0 and RECIST 1.1, 7.6% and 6.9% of patients were partial responders, 47.3% and 48.1% had SD, and 55.0% and 55.0% PD, respectively. RECIST 1.0 and RECIST 1.1 showed excellent agreement (Kappa =0.915 [95% confidence interval (CI): 0.856-0.975]). Peri-tumoral edema was documented in 32.8%, necrosis in 48.1% and both in 57.3% of cases (using RECIST 1.0). Although baseline characteristics were similar in responders and non-responders (P>0.05), responders survived significantly longer in an analysis according to RECIST 1.0: PR median (95% CI) 25.2 (range, 9.2-49.4) months vs. SD 15.8 (range, 9.3-21.1) months vs. PD 7.1 (range, 6.0-9.5) months (P<0.0001). Conclusions: RECIST 1.0 and RECIST 1.1 imaging responses provide equivalent interpretations in the assessment of hepatic tumors following 90Y-RE. Radiologic lesion responses at 3 months must be interpreted with caution due to the significant proportion of patients with peri-tumoral edema and necrosis, which may lead to an under-estimation of PR/SD. Nevertheless, 3-month radiologic responses were predictive of prolonged survival.

Original languageEnglish (US)
Pages (from-to)594-604
Number of pages11
JournalJournal of Gastrointestinal Oncology
Volume6
Issue number6
DOIs
StatePublished - Jan 1 2015

Fingerprint

Yttrium
Microspheres
Neoplasm Metastasis
Drug Therapy
Liver
Neoplasms
Edema
Necrosis
Artifacts
Colorectal Neoplasms
Confidence Intervals
Response Evaluation Criteria in Solid Tumors
Survival
Kaplan-Meier Estimate

All Science Journal Classification (ASJC) codes

  • Oncology
  • Gastroenterology

Cite this

Kennedy, Andrew S. ; Ball, David S. ; Cohen, Steven J. ; Cohn, Michael ; Coldwell, Douglas M. ; Drooz, Alain ; Ehrenwald, Eduardo ; Kanani, Samir ; Nutting, Charles W. ; Moeslein, Fred M. ; Putnam, Samuel G. ; Rose, Steven C. ; Savin, Michael A. ; Schirm, Sabine ; Sharma, Navesh K. ; Wang, Eric A. / Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases. In: Journal of Gastrointestinal Oncology. 2015 ; Vol. 6, No. 6. pp. 594-604.
@article{461350f1536a4f3ca4fa44c6ff3c8db0,
title = "Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases",
abstract = "Background: To assess response and the impact of imaging artifacts following radioembolization with yttrium-90-labeled resin microspheres (90Y-RE) based on the findings from a central independent review of patients with liver-dominant metastatic colorectal cancer (mCRC). Methods: Patients with mCRC who received 90Y-RE (SIR-Spheres{\circledR} Sirtex Medical, Sydney, Australia) at nine US institutions between July 2002 and December 2011 were included in the analysis. Tumor response was assessed at baseline and 3 months using either the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 or 1.1. For each lesion, known artifacts affecting the interpretation of response (peri-tumoral edema and necrosis) were documented. Survivals (Kaplan-Meier analyses) were compared in responders [partial response (PR)] and non-responders [stable (SD) or progressive disease (PD)]. Results: Overall, 195 patients (mean age 62 years) received 90Y-RE after a median of 2 (range, 1-6) lines of prior chemotherapy. Using RECIST 1.0 and RECIST 1.1, 7.6{\%} and 6.9{\%} of patients were partial responders, 47.3{\%} and 48.1{\%} had SD, and 55.0{\%} and 55.0{\%} PD, respectively. RECIST 1.0 and RECIST 1.1 showed excellent agreement (Kappa =0.915 [95{\%} confidence interval (CI): 0.856-0.975]). Peri-tumoral edema was documented in 32.8{\%}, necrosis in 48.1{\%} and both in 57.3{\%} of cases (using RECIST 1.0). Although baseline characteristics were similar in responders and non-responders (P>0.05), responders survived significantly longer in an analysis according to RECIST 1.0: PR median (95{\%} CI) 25.2 (range, 9.2-49.4) months vs. SD 15.8 (range, 9.3-21.1) months vs. PD 7.1 (range, 6.0-9.5) months (P<0.0001). Conclusions: RECIST 1.0 and RECIST 1.1 imaging responses provide equivalent interpretations in the assessment of hepatic tumors following 90Y-RE. Radiologic lesion responses at 3 months must be interpreted with caution due to the significant proportion of patients with peri-tumoral edema and necrosis, which may lead to an under-estimation of PR/SD. Nevertheless, 3-month radiologic responses were predictive of prolonged survival.",
author = "Kennedy, {Andrew S.} and Ball, {David S.} and Cohen, {Steven J.} and Michael Cohn and Coldwell, {Douglas M.} and Alain Drooz and Eduardo Ehrenwald and Samir Kanani and Nutting, {Charles W.} and Moeslein, {Fred M.} and Putnam, {Samuel G.} and Rose, {Steven C.} and Savin, {Michael A.} and Sabine Schirm and Sharma, {Navesh K.} and Wang, {Eric A.}",
year = "2015",
month = "1",
day = "1",
doi = "10.3978/j.issn.2078-6891.2015.082",
language = "English (US)",
volume = "6",
pages = "594--604",
journal = "Journal of Gastrointestinal Oncology",
issn = "2078-6891",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",
number = "6",

}

Kennedy, AS, Ball, DS, Cohen, SJ, Cohn, M, Coldwell, DM, Drooz, A, Ehrenwald, E, Kanani, S, Nutting, CW, Moeslein, FM, Putnam, SG, Rose, SC, Savin, MA, Schirm, S, Sharma, NK & Wang, EA 2015, 'Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases', Journal of Gastrointestinal Oncology, vol. 6, no. 6, pp. 594-604. https://doi.org/10.3978/j.issn.2078-6891.2015.082

Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases. / Kennedy, Andrew S.; Ball, David S.; Cohen, Steven J.; Cohn, Michael; Coldwell, Douglas M.; Drooz, Alain; Ehrenwald, Eduardo; Kanani, Samir; Nutting, Charles W.; Moeslein, Fred M.; Putnam, Samuel G.; Rose, Steven C.; Savin, Michael A.; Schirm, Sabine; Sharma, Navesh K.; Wang, Eric A.

In: Journal of Gastrointestinal Oncology, Vol. 6, No. 6, 01.01.2015, p. 594-604.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases

AU - Kennedy, Andrew S.

AU - Ball, David S.

AU - Cohen, Steven J.

AU - Cohn, Michael

AU - Coldwell, Douglas M.

AU - Drooz, Alain

AU - Ehrenwald, Eduardo

AU - Kanani, Samir

AU - Nutting, Charles W.

AU - Moeslein, Fred M.

AU - Putnam, Samuel G.

AU - Rose, Steven C.

AU - Savin, Michael A.

AU - Schirm, Sabine

AU - Sharma, Navesh K.

AU - Wang, Eric A.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: To assess response and the impact of imaging artifacts following radioembolization with yttrium-90-labeled resin microspheres (90Y-RE) based on the findings from a central independent review of patients with liver-dominant metastatic colorectal cancer (mCRC). Methods: Patients with mCRC who received 90Y-RE (SIR-Spheres® Sirtex Medical, Sydney, Australia) at nine US institutions between July 2002 and December 2011 were included in the analysis. Tumor response was assessed at baseline and 3 months using either the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 or 1.1. For each lesion, known artifacts affecting the interpretation of response (peri-tumoral edema and necrosis) were documented. Survivals (Kaplan-Meier analyses) were compared in responders [partial response (PR)] and non-responders [stable (SD) or progressive disease (PD)]. Results: Overall, 195 patients (mean age 62 years) received 90Y-RE after a median of 2 (range, 1-6) lines of prior chemotherapy. Using RECIST 1.0 and RECIST 1.1, 7.6% and 6.9% of patients were partial responders, 47.3% and 48.1% had SD, and 55.0% and 55.0% PD, respectively. RECIST 1.0 and RECIST 1.1 showed excellent agreement (Kappa =0.915 [95% confidence interval (CI): 0.856-0.975]). Peri-tumoral edema was documented in 32.8%, necrosis in 48.1% and both in 57.3% of cases (using RECIST 1.0). Although baseline characteristics were similar in responders and non-responders (P>0.05), responders survived significantly longer in an analysis according to RECIST 1.0: PR median (95% CI) 25.2 (range, 9.2-49.4) months vs. SD 15.8 (range, 9.3-21.1) months vs. PD 7.1 (range, 6.0-9.5) months (P<0.0001). Conclusions: RECIST 1.0 and RECIST 1.1 imaging responses provide equivalent interpretations in the assessment of hepatic tumors following 90Y-RE. Radiologic lesion responses at 3 months must be interpreted with caution due to the significant proportion of patients with peri-tumoral edema and necrosis, which may lead to an under-estimation of PR/SD. Nevertheless, 3-month radiologic responses were predictive of prolonged survival.

AB - Background: To assess response and the impact of imaging artifacts following radioembolization with yttrium-90-labeled resin microspheres (90Y-RE) based on the findings from a central independent review of patients with liver-dominant metastatic colorectal cancer (mCRC). Methods: Patients with mCRC who received 90Y-RE (SIR-Spheres® Sirtex Medical, Sydney, Australia) at nine US institutions between July 2002 and December 2011 were included in the analysis. Tumor response was assessed at baseline and 3 months using either the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 or 1.1. For each lesion, known artifacts affecting the interpretation of response (peri-tumoral edema and necrosis) were documented. Survivals (Kaplan-Meier analyses) were compared in responders [partial response (PR)] and non-responders [stable (SD) or progressive disease (PD)]. Results: Overall, 195 patients (mean age 62 years) received 90Y-RE after a median of 2 (range, 1-6) lines of prior chemotherapy. Using RECIST 1.0 and RECIST 1.1, 7.6% and 6.9% of patients were partial responders, 47.3% and 48.1% had SD, and 55.0% and 55.0% PD, respectively. RECIST 1.0 and RECIST 1.1 showed excellent agreement (Kappa =0.915 [95% confidence interval (CI): 0.856-0.975]). Peri-tumoral edema was documented in 32.8%, necrosis in 48.1% and both in 57.3% of cases (using RECIST 1.0). Although baseline characteristics were similar in responders and non-responders (P>0.05), responders survived significantly longer in an analysis according to RECIST 1.0: PR median (95% CI) 25.2 (range, 9.2-49.4) months vs. SD 15.8 (range, 9.3-21.1) months vs. PD 7.1 (range, 6.0-9.5) months (P<0.0001). Conclusions: RECIST 1.0 and RECIST 1.1 imaging responses provide equivalent interpretations in the assessment of hepatic tumors following 90Y-RE. Radiologic lesion responses at 3 months must be interpreted with caution due to the significant proportion of patients with peri-tumoral edema and necrosis, which may lead to an under-estimation of PR/SD. Nevertheless, 3-month radiologic responses were predictive of prolonged survival.

UR - http://www.scopus.com/inward/record.url?scp=84995773260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995773260&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2078-6891.2015.082

DO - 10.3978/j.issn.2078-6891.2015.082

M3 - Article

C2 - 26697190

AN - SCOPUS:84995773260

VL - 6

SP - 594

EP - 604

JO - Journal of Gastrointestinal Oncology

JF - Journal of Gastrointestinal Oncology

SN - 2078-6891

IS - 6

ER -